Damien J LaPar1, James M Isbell1, Ivan K Crosby1, John Kern1, D Scott Lim1, Edwin Fonner1, Alan M Speir2, Jeffrey B Rich3, Irving L Kron1, Gorav Ailawadi4. 1. Virginia Cardiac Surgery Quality Initiative, University of Virginia, Charlottesville, Virginia. 2. Inova Heart and Vascular Institute, Falls Church, Virginia. 3. Mid Atlantic Cardiothoracic Surgeons, Norfolk, Virginia. 4. Virginia Cardiac Surgery Quality Initiative, University of Virginia, Charlottesville, Virginia. Electronic address: gorav@virginia.edu.
Abstract
BACKGROUND: The MitraClip REALISM (Abbott Vascular, Menlo Park, CA) trial included several inclusion criteria to identify patients at high risk for conventional mitral valve (MV) surgery. This study evaluated contemporary surgical outcomes for high-risk surgical patients who met these defined criteria to serve as a benchmark to evaluate appropriateness in treatment allocation between surgical and percutaneous MV repair. METHODS: A statewide Society for Thoracic Surgeons (STS) database was queried for patients undergoing isolated mitral valve surgery over a 12-year study period from 17 different hospitals. Patients were stratified into high-risk (HR) versus non-high-risk (non-HR) cohorts based upon clinical criteria similar to those utilized in the REALISM trial. Mixed effects multivariable regression modeling was used to evaluate study endpoints including mortality, morbidity, and resource utilization. RESULTS: Of 2,440 isolated mitral operations, 29% (n = 698) were HR per REALISM criteria. Median STS Predicted Risk of Mortality (PROM) for HR patients was 6.6% compared with 1.6% for non-HR patients (p < 0.001). The HR patients more commonly underwent MV replacement as well as urgent (30% vs 19%, p < 0.001) operations. High-risk patients incurred higher morbidity and mortality (7% vs 1.6%) with longer intensive care unit (48 vs 41 hours) and hospital stays (7 vs 6 days, all p < 0.001). Among REALISM criteria, STS PROM 12% or greater and high-risk STS criteria were the only criteria associated with mortality. CONCLUSIONS: Select REALISM criteria, including reoperation with patent grafts and functional MR with ejection fraction less than 0.40, may not identify patients truly at high risk of death with surgery. In addition to conventional STS criteria, risk assessment by surgeons is essential to direct appropriate treatment allocation for high-risk mitral disease.
RCT Entities:
BACKGROUND: The MitraClip REALISM (Abbott Vascular, Menlo Park, CA) trial included several inclusion criteria to identify patients at high risk for conventional mitral valve (MV) surgery. This study evaluated contemporary surgical outcomes for high-risk surgical patients who met these defined criteria to serve as a benchmark to evaluate appropriateness in treatment allocation between surgical and percutaneous MV repair. METHODS: A statewide Society for Thoracic Surgeons (STS) database was queried for patients undergoing isolated mitral valve surgery over a 12-year study period from 17 different hospitals. Patients were stratified into high-risk (HR) versus non-high-risk (non-HR) cohorts based upon clinical criteria similar to those utilized in the REALISM trial. Mixed effects multivariable regression modeling was used to evaluate study endpoints including mortality, morbidity, and resource utilization. RESULTS: Of 2,440 isolated mitral operations, 29% (n = 698) were HR per REALISM criteria. Median STS Predicted Risk of Mortality (PROM) for HR patients was 6.6% compared with 1.6% for non-HRpatients (p < 0.001). The HR patients more commonly underwent MV replacement as well as urgent (30% vs 19%, p < 0.001) operations. High-risk patients incurred higher morbidity and mortality (7% vs 1.6%) with longer intensive care unit (48 vs 41 hours) and hospital stays (7 vs 6 days, all p < 0.001). Among REALISM criteria, STS PROM 12% or greater and high-risk STS criteria were the only criteria associated with mortality. CONCLUSIONS: Select REALISM criteria, including reoperation with patent grafts and functional MR with ejection fraction less than 0.40, may not identify patients truly at high risk of death with surgery. In addition to conventional STS criteria, risk assessment by surgeons is essential to direct appropriate treatment allocation for high-risk mitral disease.
Authors: Subhasis Chatterjee; J Scott Rankin; James S Gammie; Shubin Sheng; Sean M O'Brien; J Matthew Brennan; John C Alexander; Vinod H Thourani; Paul J Pearson; Rakesh M Suri Journal: Ann Thorac Surg Date: 2013-09-05 Impact factor: 4.330
Authors: Ted Feldman; Elyse Foster; Donald D Glower; Donald G Glower; Saibal Kar; Michael J Rinaldi; Peter S Fail; Richard W Smalling; Robert Siegel; Geoffrey A Rose; Eric Engeron; Catalin Loghin; Alfredo Trento; Eric R Skipper; Tommy Fudge; George V Letsou; Joseph M Massaro; Laura Mauri Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Patrick L Whitlow; Ted Feldman; Wes R Pedersen; D Scott Lim; Robert Kipperman; Richard Smalling; Tanvir Bajwa; Howard C Herrmann; John Lasala; James T Maddux; Murat Tuzcu; Samir Kapadia; Alfredo Trento; Robert J Siegel; Elyse Foster; Donald Glower; Laura Mauri; Saibal Kar Journal: J Am Coll Cardiol Date: 2012-01-10 Impact factor: 24.094
Authors: Liliya Paranskaya; Giuseppe D'Ancona; Ilkay Bozdag-Turan; Ibrahim Akin; Stephan Kische; Gökmen R Turan; Tim Rehders; Henrik Schneider; Bernd Westphal; Ralf Birkemeyer; Christoph A Nienaber; Hüseyin Ince Journal: Can J Cardiol Date: 2012-08-24 Impact factor: 5.223
Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Lung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala Journal: Eur J Cardiothorac Surg Date: 2012-08-25 Impact factor: 4.191
Authors: D Scott Lim; Matthew R Reynolds; Ted Feldman; Saibal Kar; Howard C Herrmann; Andrew Wang; Patrick L Whitlow; William A Gray; Paul Grayburn; Michael J Mack; Donald D Glower Journal: J Am Coll Cardiol Date: 2013-10-31 Impact factor: 24.094
Authors: Karine Toledano; Lawrence G Rudski; Thao Huynh; François Béïque; John Sampalis; Jean-François Morin Journal: Can J Cardiol Date: 2007-03-01 Impact factor: 5.223